M&A / Property
Biocure Technology Inc. enters into exclusive Letter Agreement to acquire Glorious Success Limited in Reverse Takeover Transaction
Biocure’s reverse takeover rescues cash-strapped shell with Korean MMA venture, but leaves existing holders owning just 8%
Executive Summary
- Biocure Technology entered a binding letter agreement for a reverse takeover of Glorious Success Limited (GSL), a Hong Kong holding company that controls South Korea’s Black Combat MMA promotion.
- The transaction includes a ~16.42:1 share consolidation, a minimum CAD$3.09M private placement at $2.20/share, and debt settlements totaling ~$2.71M.
- Existing CURE shareholders would hold only 8.1% of the resulting issuer, while GSL’s sellers, private placement subscribers, and bonus-share recipients take ~91.9%.
- A definitive agreement must be signed by September 15, 2026, and the deal is conditional on due diligence, shareholder and regulatory approvals, and completion of the consolidation, placement, and debt settlements.
- GSL had US$4.59M in assets, US$4.24M in liabilities, and US$2.83M in revenue at end‑2025; ~US$1.73M of liabilities will be converted to shares.
- Upon closing, the board will be reconstituted with a majority of GSL nominees, the CEO will be chosen by GSL, and the company will change its name and CSE symbol.
Material Impact
- The news is a lifeline for a pre‑revenue shell that was explicitly at risk of going concern. The reverse takeover completely changes the fundamental character of the company, from a dormant life‑sciences shell with a $23.9M accumulated deficit into an operating sports‑media business.
- However, the transaction is extremely dilutive for existing shareholders: they will own just 8.1% of the post‑deal entity. The value they retain hinges entirely on the success of the Black Combat business, which generated only US$2.83M in revenue with a thin asset‑liability balance at the end of 2025.
- The deal is a “game changer” in the sense that it prevents the likely collapse of the shell and provides a new business line, but it transfers almost all economic value to the incoming GSL stakeholders and new investors. For current shareholders, the outcome is less a windfall than a low‑probability option on a turnaround.
- The binding letter agreement still contains significant closing risk: due diligence, a definitive agreement by mid‑September, a minimum $3.09M placement, and multiple regulatory/ shareholder approvals. Failure would leave Biocure right back in its working‑capital‑deficient, going‑concern‑warned state.
- The lack of pro‑forma combined financials or detailed revenue breakdown for Black Combat limits confidence in the standalone quality of the sports‑media asset.
CURE · Price
Company Overview
- Prior-period context (from FY2025 annual filing): Biocure Technology Inc. was essentially a non‑operating shell. It reported no revenue, a net loss of $102,861, and had an accumulated deficit of $23.9 million. The company had only $41,425 in cash against a working capital deficiency of $389,541 and total assets of $2.01M (mostly a 45% investment in Korea Waterbury Uranium Limited Partnership valued at $1.97M). The previous reverse takeover attempt with Atriva Therapeutics was terminated in July 2024. Management’s MD&A flagged going‑concern doubt and stated the company’s survival depended on raising new financing.
- The planned RTO would turn this shell into a sports‑media promoter through GSL’s Black Combat business, effectively leaving Biocure’s legacy assets sidelined.